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CASE STUDY
Rifampin-warfarin interaction in a mitral 
valve replacement patient receiving rifampin 
for infective endocarditis: a case report
Amr Mohamed Fahmi1, Osama Abdelsamad1 and Hazem Elewa2*
Abstract 
Introduction: Warfarin therapy is associated with many drug interactions that may cause a significant alteration in 
its anticoagulant effect. Rifampin is a widely used antimicrobial that has major interactions with several medications 
including warfarin due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, 
CYP1A2 and CYP2C19.
Presentation: We report a case of a 34-year-old Srilankan female chronically treated with warfarin for her mitral valve 
replacement. The patient developed infective endocarditis and was started on a 6-week treatment with rifampin 
along with other antibiotics. Warfarin dose was increased from 52.5 to 210 mg/week over the course of the rifampin 
therapy, however, the INR remained subtherapeutic throughout the whole period and reached 2.4 by the end of 
rifampin therapy.
Discussion and evaluation: Anticoagulation management was challenging in the period following the end of 
rifampin therapy as well, and multiple dose adjustments starting with an increase and followed by reduction were 
required till she was stable on an 80 mg/week warfarin dose 5 weeks post-rifampin therapy.
Conclusion: Our findings suggest the importance of close monitoring of warfarin therapy during and after the use 
of rifampin to minimize the risks of under and over-anticoagulation and improve the safety and efficacy of warfarin 
therapy.
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Introduction
For over 60  years, warfarin has been the mainstay anti-
coagulant used in the prevention and treatment of 
thromboembolic complications in patients with atrial 
fibrillation, venous thromboembolism, prosthetic heart 
valves, and coronary artery disease (Nutescu et al. 2006). 
Because of its narrow therapeutic index and the substan-
tial interpatient variability associated with its dosing, 
careful monitoring of warfarin is strongly recommended 
by current practice guidelines to minimize the risks asso-
ciated with warfarin’s inadequate dosing and ensure opti-
mal outcomes for anticoagulated patients (Horton and 
Bushwick 1999; You et al. 2012). Despite its wide-spread 
use, management of patients on warfarin treatment 
is associated with many challenges. These challenges 
include therapeutic dose inter- and intra-patient variabil-
ity, drug and food interactions, environmental factors, 
co-morbidities, and narrow therapeutic index (Nutescu 
et al. 2006). Accordingly, close monitoring and individu-
alized dosing based on International normalized ratio 
(INR) measurement is warranted to confirm effective 
level of anticoagulation (Ageno et al. 2012).
Warfarin is administered as a racemic mixture, the R 
and S enantiomers. The more potent, S enantiomer, is sub-
ject to approximately 90  % oxidative metabolism, mainly 
through the Cytochrome P450 2C9 (CYP2C9) enzyme 
of the Cytochrome P450 system and to a minor extent by 
CYP3A4. On the other hand, the less potent, R enantiomer, 
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is subject to approximately 60  % oxidative metabolism, 
primarily through CYP1A2 and CYP3A4, and to a minor 
extent through CYP2C19 (Kaminsky and Zhang 1997; 
Miners and Birkett 1998; Cropp and Bussey 1997).
Rifampin is a widely used antimicrobial for the treat-
ment of challenging and life-threatening infections such 
as tuberculosis, meningitis, osteomyelitis and endocardi-
tis (Baciewicz et al. 2008). Due to its proven efficacy in the 
management of infective endocarditis, American Heart 
association (AHA), and the European Society for cardiol-
ogy (ESC),recommend rifampin in treatment of prosthetic 
valve endocarditis caused by Coagulase-Negative Staphy-
lococci species in combination with other antimicrobial 
agents (Gould et al. 2012; Newburger et al. 2004). Rifampin 
is known to have major interactions with several medica-
tions due to its strong P-glycoprotein and liver enzyme 
inducer activity especially on CYP2C9, CYP3A4, CYP1A2 
and CYP2C19 (Horn et  al. 2007; Ohno et  al. 2008). 
Rifampin’s concomitant use with warfarin results in a clini-
cally significant drug–drug interaction. This interaction 
leads to accelerated warfarin’s clearance and ultimately a 
reduction in its anticoagulant effect (Strayhorn et al. 1997; 
Baciewicz et al. 2008). There are several, well-documented 
cases of potential interactions during concurrent rifampin-
warfarin use (Lee and Thrasher 2001; Martins et al. 2013; 
Krajewski 2010; Maina et al. 2013). This interaction affects 
warfarin dose required to achieve and maintain therapeu-
tic INR and may increase this dose up to six times to reach 
target therapeutic INR. If warfarin dose is not adjusted 
accordingly, this may lead to subtherapeutic INR values 
and increase in the risk of clinical complications (Kim et al. 
2007; Tong et al. 2014; Krajewski 2010; Lee and Thrasher 
2001). This interaction remains clinically significant dur-
ing, and weeks after discontinuation of rifampin. Addi-
tionally, risk of bleeding after rifampin discontinuation has 
been reported (Martins et al. 2013).
The aim of this case report is to address the effect of 
rifampin–warfarin interaction in a patient with endo-
carditis who has been receiving a stable and therapeutic 
warfarin dose for mechanical heart valve replacement. 
The patient has provided consent for the use of his per-
sonal and medical information in this case report.
Presentation
A 34-year-old Srilankan female with a history of rheu-
matic heart disease, underwent mitral valve replacement 
in 1994 and was on anticoagulation ever since with war-
farin and a target INR of (2.5–3.5). She was maintained 
on warfarin weekly dose of 52.5 mg (7.5 mg daily) since 
she started follow-up at our pharmacist-managed antico-
agulation clinic in late 2013.
On the 23rd of October, 2014, the patient started to 
have fever with chills and was admitted to the hospital 
and diagnosed with prosthetic valve infective endocar-
ditis. Initially, the patient was started on vancomycin 
(1800 mg/day), gentamicin (80 mg/day), ceftriaxone (2 g/
day) and rifampin (600  mg/day). The patient was using 
her usual warfarin dose (7.5 mg daily) and her INR was 
2.6. Two days later, and she complained of heavy menses 
and her hemoglobin dropped to 7.5 g/dl. INR increased 
to 4.4 at that time and warfarin was stopped.
Three days later, some changes were made to her anti-
biotic regimen where vancomycin was replaced by dap-
tomycin (300  mg/day). Her gentamycin was stopped 
after 3  weeks from its initiation while the rest of the 
antibiotics (daptomycin, ceftriaxone and rifampin) were 
continued for three more weeks to complete a six-week 
course.
After being held for 5  days due to the bleeding and 
drop in hemoglobin, warfarin was restarted and an INR 
of 1.6 was recorded at that time. Since warfarin resump-
tion, the patient’s INR became subtherapeutic likely due 
to the interaction with rifampin. Conservative incre-
ments of warfarin dose were made during her hospitali-
zation period which continued for almost a month. Upon 
discharge on the 18th of November, INR was 1.3 and 
warfarin weekly dose was 105  mg (15  mg/day), she was 
then followed-up again at the anticoagulation clinic and 
was bridged with therapeutic dose enoxaparin (1  mg/
kg subcutaneous every 12 h). Warfarin weekly dose was 
increased gradually from 105 to 155 mg over the follow-
ing 2 weeks but her INR remained subtherapeutic at all 
time and increased slightly from 1.3–1.8.
On the 3rd of December, the patient had symptoms 
of palpitations and her electrocardiogram showed atrial 
flutter with rapid ventricular response of 147 beats per 
minute and she was admitted again to the cardiac care 
unit for rate control were she was maintained on meto-
prolol (50  mg/day). Six days later, the patient’s antibiot-
ics including rifampin were stopped after completing a 
total of 6-week treatment course for endocarditis. The 
following day, she was discharged with an INR of 2.4 and 
a warfarin weekly dose of 210 mg daily (30 mg/day). The 
first significant change in her INR was a drop to 1.9 (no 
change in dosing was made at this point) and she was 
followed-up every 2–3  days. Her INR readings gradu-
ally increased but were all in therapeutic range (INR on 
17/12/2014 was 3.3). Four days later, (11 days post-anti-
biotics discontinuation, the patient had a supratherapeu-
tic INR of 10.2 for which warfarin was held for 2  days 
and then resumed at a reduced-dose of 7.5 mg/day (her 
routine dose prior to rifampin initiation). Patient’s INR 
did not adequately respond to this dose reduction and 
became subtherapeutic. Warfarin dose was increased 
gradually while bridging with therapeutic dose enoxapa-
rin till she reached a maintenance dose of (10  mg daily 
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except 15  mg twice/week) (a weekly dose of 80  mg) on 
15/1/2015 where her INR reached 2.5 (Fig. 1).
In summary, warfarin dose was increased from 52.5 to 
210  mg/week over the course of the 6-week treatment 
with antibiotics for her infective endocarditis. Due to the 
patient’s risk of stroke and the difficulty to reach therapeu-
tic INR, she was bridged using enoxaparin. The patient’s 
INR remained subtherapeutic throughout the whole period 
when she received rifampin concomitantly with warfarin, 
and reached 2.4 by the end of rifampin therapy. Anticoagu-
lation management was challenging in the period following 
the end of her rifampin therapy, and multiple dose adjust-
ments starting with an increase and followed by gradual 
reduction were required till she was stable on an 80  mg/
week warfarin dose 5 weeks post-rifampin therapy.
Discussion
In this case report, we observed the challenging manage-
ment of warfarin therapy when rifampin therapy along 
with other antibiotics (ceftriaxone, gentamicin and dap-
tomycin) were used concomitantly in a patient previously 
stable on anticoagulation therapy with warfarin for stroke 
prevention from her mechanical mitral valve replace-
ment. While on rifampin, she required about fourfold 
increase in her warfarin dose and the addition of bridging 
therapy using low molecular weight heparin (LMWH) to 
maintain proper anticoagulation due to failure in achiev-
ing therapeutic INR with warfarin. After discontinuation 
of rifampin, the drug–drug interaction effect remained 
for almost 5  weeks. After the offset of rifampin effect, 
warfarin maintenance dose was noticed to be 150  % 
higher than its baseline prior to rifampin initiation (80 vs 
52.5 mg/week). It is also important to note that the sud-
den elevation and drop in INR associated with the ini-
tiation and discontinuation of the antibiotic treatment, 
respectively is likely mediated by the interaction between 
warfarin and ceftriaxone. A previous report has shown 
that concomitant use of ceftriaxone and warfarin can 
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Fig. 1 This graph represents the daily warfarin dose, INR, and concomitant rifampin therapy over time. The x-axis represents time when the INR was 
measured. The left y-axis represents the INR units and is shown by the black diamond points. The right Y-axis represents warfarin dose administered 
in milligrams/day and is shown by the vertical bars. The therapeutic range is indicated between the two dotted lines (2.5–3.5). The time period of 
concomitant rifampin administration is shown as the horizontal solid 2-way arrow
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lead to a significant elevation in INR and warfarin antico-
agulant effect (Clark and Burns 2011).
Several reports have previously described the inter-
action between rifampin and warfarin and the effect of 
rifampin on the anticoagulation effect of warfarin during 
concomitant use of both medications (Lee and Thrasher 
2001; Martins et  al. 2013; Krajewski 2010; Maina et  al. 
2013). Lee et  al. described a case for a patient who was 
started on rifampin for active tuberculosis and was 
started on warfarin 4  months later for left ventricular 
thrombus. The warfarin dosage required to attain thera-
peutic INR was significantly higher when the patient 
received concomitant rifampin (233  % higher) than the 
dose required after rifampin discontinuation (Lee and 
Thrasher 2001). Similar reports were described by others 
(Self and Mann 1975; Almog et al. 1988).
Additional case studies described patients who were 
started on rifampin 600  mg and warfarin around the 
same time. The warfarin dose was reduced by about 
50  % to maintain therapeutic INR after discontinuation 
of rifampin (Krajewski 2010; Romankiewicz and Ehrman 
1975).
Other reports have described the interaction between 
warfarin and rifampin in patients already on chronic 
warfarin therapy (Martins et  al. 2013; Tong et  al. 2014; 
Kim et al. 2007). Similar to our case report, these reports 
described the interaction resulting from the addition 
of rifampin in patients already receiving chronic war-
farin therapy. Sequential increase in warfarin dose was 
required to reach therapeutic level with frequent INR 
monitoring. After discontinuation of rifampin, the war-
farin dosage requirement was reduced gradually to avoid 
supratherapeutic INR until reaching therapeutic level.
Collectively, all previously described case studies and 
case series agree on the difficulty of achieving thera-
peutic level of anticoagulation despite escalation of 
warfarin dose due to the interaction with rifampin. The 
increments recorded in warfarin dose vary between 
twofold to sixfold compared to the dose required when 
patient is not on rifampin. The onset of interaction and 
the requirement to increase warfarin dose seem to have 
faster timeline (7–14 days) compared to the offset of the 
interaction which may require tapering the warfarin dose 
down over weeks. There are wide inter-patient variability 
in the extent, onset and offset of the warfarin-rifampin 
interaction.
Conclusion
This case study confirms previously reported studies on 
the interaction between warfarin and rifampin. It also 
demonstrates that this interaction is clinically significant 
and can be very critical in high-risk patients such as those 
receiving warfarin for mechanical valve replacement. 
Our findings suggest the importance of close monitoring 
of warfarin therapy during and after the use of rifampin 
to minimize the risks of under and over-anticoagulation 
and improve the safety and efficacy of warfarin therapy.
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